Literature DB >> 17303950

Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia.

Necat Yilmaz1, Hasan Herken, Hülya Kanbur Cicek, Ahmet Celik, Muhittin Yürekli, Omer Akyol.   

Abstract

OBJECTIVE: To investigate the levels of serum cortisol, dehydroepiandrosterone sulfate (DHEA-S), nitric oxide (NO) and adrenomedullin (AM) in schizophrenic patients. SUBJECTS AND METHODS: Sixty-six male patients with chronic schizophrenia and 28 normal male subjects participated in this study. The duration of disease was 145 +/- 120 (mean +/- SD) months. Serum levels of cortisol and DHEA-S were measured by electrochemiluminescence; plasma nitrite levels as an index of NO were measured with the Griess reaction, while plasma AM concentration was measured by using high-performance liquid chromatography.
RESULTS: Patients (12.48 +/- 3.2 microg/dl), as compared to controls (10.31 +/- 3.1 microg/dl), had higher levels of baseline cortisol (p < 0.05). DHEA-S levels were lower in patients though this did not reach statistical significance (302 +/- 156 microg/dl compared to control, 322 +/- 96 microg/dl, p > 0.05). The mean levels of plasma AM and NO in the schizophrenic group (44.33 +/- 5.07 pmol/l and 36.27 +/- 17.6 micromol/l) were significantly higher than the levels in the control group (14.56 +/- 4.03 pmol/l and 32.54 +/- 7.14 micromol/l; p < 0.001, p < 0.03, respectively). There was a positive association between duration of disease and cortisol/DHEA-S ratio and cortisol level.
CONCLUSION: The data show that schizophrenia is associated with abnormal levels of cortisol, DHEA-S, NO and AM. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303950     DOI: 10.1159/000098367

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  17 in total

Review 1.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

2.  A NOS1 variant implicated in cognitive performance influences evoked neural responses during a high density EEG study of early visual perception.

Authors:  Therese O'Donoghue; Derek W Morris; Ciara Fahey; Andreia Da Costa; John J Foxe; Doreen Hoerold; Daniela Tropea; Michael Gill; Aiden Corvin; Gary Donohoe
Journal:  Hum Brain Mapp       Date:  2011-04-21       Impact factor: 5.038

3.  Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat.

Authors:  Antonios Boultadakis; Nikolaos Pitsikas
Journal:  Neuropsychopharmacology       Date:  2010-07-21       Impact factor: 7.853

4.  Cortisol and dehydroepiandrosterone sulfate in patients with schizophrenia spectrum disorders with respect to cognitive performance.

Authors:  Błażej Misiak; Patryk Piotrowski; Magdalena Chęć; Jerzy Samochowiec
Journal:  Compr Psychoneuroendocrinol       Date:  2021-03-03

5.  Genome-wide identification of new Wnt/beta-catenin target genes in the human genome using CART method.

Authors:  Christian Hödar; Rodrigo Assar; Marcela Colombres; Andrés Aravena; Leonardo Pavez; Mauricio González; Servet Martínez; Nibaldo C Inestrosa; Alejandro Maass
Journal:  BMC Genomics       Date:  2010-06-01       Impact factor: 3.969

6.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

7.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

8.  Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects.

Authors:  Albert T Higgins-Chen; Marco P Boks; Christiaan H Vinkers; René S Kahn; Morgan E Levine
Journal:  Biol Psychiatry       Date:  2020-02-08       Impact factor: 13.382

Review 9.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

10.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.